Federal Circuit Denies Rehearing on Device Patents in Orange Book

The Federal Circuit’s denial of rehearing in the Orange Book device patent dispute between Teva and Amneal may sound like a headline written exclusively for patent lawyers, regulatory specialists, and people who enjoy alphabet soup for breakfast. But the issue is bigger than a courtroom procedural update. It touches drug prices, generic competition, asthma inhalers, FDA patent listings, and the delicate balance between rewarding pharmaceutical innovation and preventing patent listings from becoming a regulatory traffic jam.

At the center of the case is a deceptively simple question: can a brand-name drug company list device-related patents in the FDA’s Orange Book when those patents do not claim the approved drug’s active ingredient? In Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, the Federal Circuit’s answer was no. When Teva asked the court to reconsider that answer, the court denied both panel rehearing and rehearing en banc, leaving its earlier ruling intact.

For drug manufacturers, generic companies, investors, patients, and healthcare policy watchers, the decision is a major signal. The Orange Book is not a junk drawer for every patent that might be connected to a drug product. It is a carefully defined regulatory tool, and the Federal Circuit has now made clear that device patents must have a stronger connection to the approved drug itself if they are going to stay listed.

What Happened in the Teva v. Amneal Orange Book Case?

The dispute involved Teva’s ProAir HFA inhalation aerosol, a metered-dose inhaler used to treat or prevent bronchospasm. The active ingredient in ProAir HFA is albuterol sulfate. Teva had listed several patents in the FDA’s Orange Book for the product, including five patents that related to inhaler device components such as dose counters and canisters.

Amneal filed an abbreviated new drug application, commonly called an ANDA, seeking approval for a generic version of ProAir HFA. Because Teva’s patents were listed in the Orange Book, Amneal had to address them through the Hatch-Waxman framework. Teva then sued Amneal for patent infringement. Amneal counterclaimed that the five device-related patents were improperly listed and should be delisted from the Orange Book.

The District of New Jersey agreed with Amneal. The district court concluded that the patents did not claim the drug for which Teva submitted its new drug application because they did not claim or even mention albuterol sulfate, the active ingredient. Instead, the patents focused on device components of the inhaler. The district court ordered Teva to delist the five patents.

Teva appealed to the Federal Circuit. In December 2024, the Federal Circuit affirmed the delisting order. Teva then sought rehearing, asking the court to revisit the decision. On March 3, 2025, the Federal Circuit denied rehearing. That denial turned the original panel opinion from an important ruling into a firmer guidepost for Orange Book patent listing strategy.

Why the Orange Book Matters

The FDA’s Orange Book, formally known as Approved Drug Products with Therapeutic Equivalence Evaluations, is a key piece of the U.S. drug approval system. It identifies approved drug products, therapeutic equivalence information, patent listings, and exclusivity data. For generic drug companies, the Orange Book is like a regulatory map. It tells them what patents they must certify against before seeking approval to market a generic version of a brand-name drug.

Under the Hatch-Waxman Act, a brand-name drug company submits patent information to the FDA for patents that claim the approved drug or an approved method of using the drug. When a generic applicant files an ANDA, it must make certifications about those listed patents. A Paragraph IV certification, for example, asserts that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Here is where things get spicy, at least by regulatory law standards. If the brand company sues the generic applicant after a Paragraph IV certification, FDA approval of the generic product can be stayed for up to 30 months. That stay can be enormously valuable for a brand company and enormously frustrating for a generic competitor. In the pharmaceutical world, 30 months is not a coffee break. It can mean hundreds of millions of dollars, delayed market entry, and continued higher prices for patients and payors.

The Federal Circuit’s Core Holding: The Patent Must Claim the Drug

The Federal Circuit focused on statutory language requiring that a listable patent must claim the drug for which the applicant submitted the application. Teva argued that its device patents were listable because the claimed device components were part of the approved inhaler product. In Teva’s view, a patent could qualify if it claimed a component of the drug-device combination.

The Federal Circuit rejected that interpretation. The court explained that a patent does not “claim the drug” merely because it reads on a part of an approved product or because infringement might be asserted. Claiming and infringement are not the same thing. A patent claim defines the invention. It does not automatically cover every commercial product that might practice or include some claimed feature.

Most importantly, the court held that to claim the drug for Orange Book listing purposes, the patent must claim at least the active ingredient of the approved drug. In this case, that meant albuterol sulfate. Because the device patents at issue claimed inhaler components rather than albuterol sulfate, the court concluded they did not meet the statutory requirement for Orange Book listing.

Why the Rehearing Denial Is Important

A rehearing denial is not the same as a brand-new opinion, but it can be extremely meaningful. When the Federal Circuit denied Teva’s request for panel rehearing and rehearing en banc, it declined to soften, revise, or reconsider the earlier ruling. That means the active-ingredient-focused interpretation remains the controlling Federal Circuit decision unless changed by the Supreme Court, Congress, FDA rulemaking, or future case law.

The denial also matters because several industry participants were watching closely. Drug-device combination products are everywhere: inhalers, autoinjectors, prefilled pens, injector systems, nasal sprays, and other delivery platforms. Many of these products involve both pharmaceutical science and mechanical engineering. The harder question is whether a patent on the engineering side belongs in the Orange Book when it does not claim the drug’s active ingredient.

After this decision, companies cannot assume that a patent covering a delivery feature is automatically Orange Book eligible. The patent may still be valuable. It may still be enforceable in ordinary patent litigation. But it may not be entitled to the special regulatory consequences that come with Orange Book listing.

Device Patents Are Not DeadBut Their Orange Book Path Is Narrower

One common misunderstanding is that the Federal Circuit’s decision makes device patents useless. That is not true. Device patents can remain powerful intellectual property assets. A patent covering an inhaler dose counter, injector mechanism, safety shield, cap design, or drug delivery component may still be enforced against competitors if the accused product infringes the claims.

The difference is where and how the patent operates. A patent outside the Orange Book can still be litigated. The patent owner can still seek damages or injunctive relief if legal standards are met. What the patent owner may lose is the automatic Hatch-Waxman machinery that can delay FDA approval through the 30-month stay.

Think of it like a parking pass. Owning a car does not mean you can park in every reserved space. Likewise, owning a device patent does not mean it automatically earns a reserved spot in the Orange Book. The Orange Book has rules, and according to the Federal Circuit, those rules require the patent to claim the approved drug, including at least the active ingredient.

Impact on Generic Drug Competition

The decision is a win for generic manufacturers challenging device-heavy Orange Book listings. A generic company that faces a wall of listed device patents may now have a stronger basis to argue that some of those patents do not belong in the Orange Book if they do not claim the active ingredient or the approved drug product in the required way.

For patients and payors, the potential impact is straightforward: fewer improper listings may mean fewer artificial delays to generic competition. Generic entry is one of the most important price-lowering forces in the U.S. prescription drug market. When improper patent listings delay competition, consumers may pay more for longer. The Federal Trade Commission has repeatedly expressed concern that inaccurate Orange Book listings can block or slow generic alternatives, especially for inhalers, autoinjectors, and other drug-device products.

That does not mean every brand patent is suspicious or every generic challenge is righteous. Pharmaceutical innovation is expensive, risky, and heavily regulated. Companies deserve meaningful patent protection for real inventions. But the Orange Book is not meant to transform every engineering improvement into a regulatory barrier against generic approval.

Impact on Brand-Name Drug Companies

For brand-name manufacturers, the ruling creates a clear compliance message: review Orange Book listings carefully. Device-related patents should be evaluated claim by claim, not merely by asking whether the patented feature appears somewhere in the commercial product.

Brand companies may now pay closer attention to claim drafting. If a company wants a patent to be Orange Book eligible, it may consider whether the claims properly recite the active ingredient or a formulation containing that active ingredient. However, companies must be careful. Drafting claims merely to satisfy listing rules without supporting real patentability can create its own legal headaches. Patent law, like a skeptical editor, does not reward vague padding.

The decision may also affect lifecycle management strategies. For years, some companies have used patents on delivery devices, formulations, methods of use, and product improvements to extend protection around mature drugs. Some of these strategies are legitimate. Others draw antitrust scrutiny when they appear designed mainly to delay lower-cost competition. The Teva-Amneal decision raises the cost of aggressive listing strategies that stretch the Orange Book beyond its statutory purpose.

How This Fits Into the FTC’s Orange Book Crackdown

The Federal Circuit’s decision did not happen in a vacuum. The FTC has been challenging allegedly improper Orange Book patent listings, particularly for products such as asthma inhalers, epinephrine autoinjectors, and diabetes or weight-loss drug delivery systems. The agency’s basic concern is that certain device patents may be listed in ways that delay generic or follow-on competition without satisfying Orange Book requirements.

In the Teva-Amneal dispute, the FTC supported the position that the device patents should be removed. The agency has argued that improper listings can function as anticompetitive barriers because they may trigger regulatory delays even when the patent does not actually claim the approved drug.

The Federal Circuit’s active ingredient rule gives challengers a sharper tool. Instead of debating only whether a device patent is useful, valuable, or infringed, courts and litigants can ask a more targeted question: does the patent claim the approved drug, including at least the active ingredient? If not, the listing may be vulnerable.

Examples: Inhalers, Autoinjectors, and Drug Delivery Devices

The ruling is especially relevant for combination products. Consider an asthma inhaler. The active ingredient may be a bronchodilator or corticosteroid, while the device includes valves, actuators, counters, canisters, and mouthpieces. A patent on a dose counter may be innovative and commercially important. But if the claims do not recite the active ingredient or the approved drug product, the patent may not qualify for Orange Book listing under the Federal Circuit’s reasoning.

The same logic may apply to autoinjectors. A patent might cover a spring mechanism, needle shield, safety lock, or injection confirmation window. Those features can improve usability and safety. Still, if the patent claims only the mechanical device and not the drug, the patent owner may face a challenge if it lists that patent in the Orange Book.

Prefilled pens for diabetes or weight-loss medications raise similar questions. A delivery mechanism can be clever, expensive to develop, and highly valuable. But clever mechanics alone may not be enough for Orange Book eligibility if the patent does not claim the active pharmaceutical ingredient or a qualifying drug product.

Practical Lessons for Pharmaceutical Teams

1. Audit Existing Orange Book Listings

Companies should review listed patents, especially those involving device components. The key question is not whether the patent is valuable. The key question is whether the patent meets the statutory listing standard as interpreted by the Federal Circuit.

2. Separate Patent Value From Listing Eligibility

A patent can be strong but not listable. That distinction is now critical. Legal, regulatory, and business teams should avoid treating Orange Book listing as a default reward for every product-related patent.

3. Prepare for More Delisting Counterclaims

Generic applicants are likely to use this decision when challenging device-heavy listings. Delisting counterclaims may become more common, especially in markets where delivery devices are central to the product’s commercial success.

4. Watch Antitrust Risk

Improper listing can create more than a patent dispute. It may invite antitrust allegations, FTC attention, and private litigation. In a world where drug pricing is already under a microscope, questionable Orange Book listings are not exactly wearing an invisibility cloak.

Real-World Experiences and Observations From the Orange Book Patent Front Lines

One of the most useful ways to understand this dispute is to imagine the experience of the different teams who must live with the Orange Book every day. For a brand-name pharmaceutical company, the Orange Book can feel like a protective fence around years of research, investment, regulatory work, and commercial planning. When a company develops a drug-device product, the device is not an afterthought. A patient using an inhaler, autoinjector, or prefilled pen depends on the device to deliver the medicine properly. If the device fails, the therapeutic promise of the active ingredient may never reach the patient in a meaningful way.

That is why brand companies often view device patents as part of the product’s real-world innovation story. A dose counter can help patients know when an inhaler is running low. A safety mechanism can reduce accidental needle sticks. A better actuator can improve consistency. From the business side, it feels natural to say, “This is part of our approved product, so the patent should be listed.” The Federal Circuit’s decision pushes back on that instinct. It says the Orange Book is not based only on commercial integration. It is based on statutory eligibility.

For generic manufacturers, the experience is very different. A generic company may see an Orange Book crowded with patents that do not appear to claim the active ingredient. Each listing can create cost, delay, and uncertainty. Even if the generic company believes it does not infringe, it must decide whether to certify, litigate, design around, wait, or challenge the listing. That is not a small administrative chore. It can determine whether a generic product reaches the market this year, next year, or several years from now.

For regulatory lawyers, this case is a reminder that words matter. “Claims the drug” is not casual language. It is a legal threshold. A patent claim is not a marketing brochure, a product description, or a broad statement of usefulness. It is the legal boundary of the invention. When the court separated “claiming” from “infringement,” it made a practical point that will echo through future listing analyses: a product can include a patented feature without the patent claiming the approved drug for Orange Book purposes.

For patients, the experience is simpler and more personal. Most people do not care whether a delay comes from a device patent, a formulation patent, or a procedural stay. They care whether their inhaler is affordable and available. If an Orange Book listing improperly delays a generic inhaler, the legal technicality becomes a pharmacy-counter problem. That is why this case matters beyond law firm alerts and regulatory memos. The Orange Book may be a specialized database, but its consequences can show up in household budgets.

The biggest lesson is balance. Strong patents should protect real innovation. But Orange Book listings should be reserved for patents that Congress allowed into that system. The Federal Circuit’s denial of rehearing reinforces that balance and gives companies a clearer, if stricter, rule for future decisions.

Conclusion

The Federal Circuit’s denial of rehearing in the Teva-Amneal Orange Book dispute is a major development for pharmaceutical patent strategy. The court left standing its ruling that patents claiming only device components of an approved drug-device product do not qualify for Orange Book listing unless they claim at least the active ingredient of the approved drug.

For brand companies, the decision demands a more disciplined approach to Orange Book listings. For generic companies, it offers a stronger path to challenge listings that may delay competition. For regulators and antitrust enforcers, it supports a broader push toward accuracy and accountability in patent submissions. And for patients, the practical hope is that fewer improper listings may help lower-cost generics reach the market sooner.

The Orange Book remains essential to the Hatch-Waxman system, but this case makes one thing clear: not every patent connected to a drug product belongs there. Device innovation matters. Active ingredients matter. And in Orange Book law, the difference between the two can decide whether a patent gets a regulatory spotlight or waits outside the velvet rope.

Note: This article is for general informational and educational purposes only. It is not legal advice, medical advice, or a substitute for consultation with a qualified attorney, regulatory professional, or healthcare provider.